Last reviewed · How we verify
Mixed anxiety and depressive disorder
Approved treatments
- Chlordiazepoxide Hydrochloride · Bausch Health
- MAPROTILINE
- Trilafon
- Endep · AstraZeneca
- Amitryptiline · Mahatma Gandhi Institute of Medical Sciences
- Xanax · National Taiwan University Hospital
- Xanax · Generic (originally Upjohn/Pfizer)
Short-acting, high-potency benzodiazepine that enhances GABA-A receptor activity, providing rapid anxiolytic relief.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mixed anxiety and depressive disorder patent landscape — cliff calendar, originator estates, attackable patents
- Mixed anxiety and depressive disorder treatment landscape brief
- Mixed anxiety and depressive disorder treatment updates RSS
Frequently asked questions about Mixed anxiety and depressive disorder
What drugs treat Mixed anxiety and depressive disorder?
Tracked treatments include Chlordiazepoxide Hydrochloride, MAPROTILINE, Trilafon, Endep, Amitryptiline, Xanax.
What is the treatment for Mixed anxiety and depressive disorder?
Standard treatment for Mixed anxiety and depressive disorder includes Chlordiazepoxide Hydrochloride, MAPROTILINE, Trilafon, Endep, Amitryptiline. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mixed anxiety and depressive disorder patent cliff · Mixed anxiety and depressive disorder CI report
- Treatment: Chlordiazepoxide Hydrochloride · Bausch Health
- Treatment: MAPROTILINE
- Treatment: Trilafon
- Treatment: Endep · AstraZeneca
- Treatment: Amitryptiline · Mahatma Gandhi Institute of Medical Sciences
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing